

Furoscix® (furosemide) - Expanded indication

- On August 12, 2024, <u>scPharmaceuticals announced</u> the <u>FDA approval</u> of <u>Furoscix (furosemide)</u>, for the treatment of congestion due to fluid overload in adult patients with chronic heart failure.
 - Furoscix was previously approved for this indication in patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
 - The updated indication now includes patients with NYHA Class IV chronic heart failure.
- Patients with NYHA Class IV chronic heart failure are the most symptomatic patients and those
 with the greatest limitation on physical activity. This population represents approximately 10% of
 all heart failure cases.
- Furoscix is administered as a subcutaneous single-use, on-body infusor with prefilled cartridge that is pre-programmed to deliver 30 mg of furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours.
 - Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.
 - Furoscix is intended for use in a setting where the patient can limit their activity for the duration of administration.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.